The IPX Series and Its Applications in Education

The AtlasIED IPX Series is the evolution of the IP endpoint category, adding to the foundational features that have served the market for decades by bringing elevated display capabilities and modern styling – and the solutions have a critical role to play in the educational space.

To outline that role, AtlasIED Business Development Manager – Education Manny Kitagawa answered some frequently asked questions and lent his front-line insight to the topic.

One benefit of the IPX Series is its use of standard Ethernet protocols, which makes operation and maintenance simpler for IT professionals.

The Series also has the ability to use API shared by software partners, which allows for visual notifications, color codes and more. Color codes, in particular, can prove critical in a learning environment, allowing the campus to display “normal” alerts, emergencies and more for those with hearing challenges.

In addition to day-to-day communication requirements, such as bell schedules, the IPX Series of IP endpoints offers elevated functionality in its collaboration with third-party systems like access control, classroom multimedia systems, and more.

To learn more, visit atlasied.com/ipx-series-overview.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More